Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

已完结 10 由行止发布于 2025/9/5 22:31:23

DOI:10.1056/NEJMoa2502099
作者：Giannis Mountzios,?Longhua Sun,?Byoung Chul Cho,?Umut Demirci,?Sofia Baka,?Mahmut Gümü?,?Antonio Lugini,?Bo Zhu,?Yan Yu,?Ippokratis Korantzis,?Ji-Youn Han,?Tudor-Eliade Ciuleanu,?Myung-Ju Ahn,?Pedro
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1056/NEJMoa2502099

New England Journal of Medicine (NEJM)

Abstract：Background: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Optimal bivariate order-replacement policies for a multi-state repairable system with reliability constraint